An observational study in Hepatocellular Carcinoma and Liver Transplantation, sponsored by Ningbo Medical Center Lihuili Hospital. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Ningbo Medical Center Lihuili Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for liver transplantation. The primary objective is to assess the outcomes of these "intention-to-treat" patients who received locoregional therapies (LRT, such as TACE or radiotherapy) in combination with systemic therapy (anti-VEGF/Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors) as a "conversion therapy" prior to potential transplantation. This approach is distinct from traditional bridging or down-staging therapies by incorporating more aggressive systemic regimens. The study plans to enroll 300 subjects. The exposure group will include approximately 100 patients beyond UCSF criteria who received the combined conversion therapy between January 2020 and December 2024. A control group of about 200 patients who met the UCSF criteria and were directly listed for transplantation in the same period will be used for comparison. Data will be collected from medical records and the China Liver Transplant Registry (CLTR), with follow-up until December 2025.
Primary outcome measures include:
Objective Response Rate (ORR) of conversion therapy per mRECIST. Rate of successful down-staging to meet UCSF criteria.
1-, 2-, and 3-year overall survival (OS) rates of the intention-to-treat population.
Actual liver transplantation rate after successful conversion. Post-transplant 1-, 2-, and 3-year OS and recurrence-free survival (RFS) rates.
Secondary outcomes involve:
Safety profiles of both conversion therapy and subsequent transplantation. Analysis of factors influencing conversion success and treatment efficacy. Determination of an optimal washout period for Immune Checkpoint Inhibitors prior to transplantation.
The study seeks to provide high-level evidence for optimizing pre-transplant conversion strategies for advanced HCC patients currently outside standard transplant criteria.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
This study's planned enrollment of 300 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Ningbo Medical Center Lihuili Hospital is the lead sponsor of 16 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This retrospective, single-center cohort study plans to include 300 patients with HCC. All patients were managed at the study center between January 1, 2020, and December 31, 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HCC patients receiving conversion therapy beyond UCSF criteria
Combination Product: Locoregional Therapy (LRT) + Systemic Drug Therapy
HCC patients within UCSF Criteria Cohort
Treatment regimens, doses, and durations varied based on individual clinical decisions and are collected retrospectively.
Objective Response Rate (ORR)
Proportion of patients achieving a Complete Response (CR) or Partial Response (PR) according to mRECIST criteria during the conversion therapy period.
Time frame: From the start of conversion therapy until the completion of therapy (assessed up to 24 months).
Successful Down-staging Rate to UCSF Criteria
Proportion of patients whose tumor burden is reduced to meet the UCSF transplant criteria after conversion therapy, based on imaging and tumor marker assessment.
Time frame: From the start of conversion therapy until the date of meeting UCSF criteria or therapy termination (assessed up to 24 months).
1/2/3-year Overall Survival (OS) Rate
The proportion of patients who received conversion therapy and are still alive at 1, 2, and 3 years after the transplantation surgery, analyzed using the Kaplan-Meier method.
Time frame: From the initiation of conversion therapy, assessed at 1, 2, and 3 years.
No study locations are listed for this record.
Plan to share: Undecided — A specific plan for sharing de-identified individual participant data (IPD) from this retrospective study is under development. The final decision will depend on several factors, including but not limited to: institutional review board (IRB) approval, compliance with data privacy regulations, and the establishment of appropriate data use agreements. If shared, the data would likely include demographic, clinical treatment, tumor response, and survival outcome data to support validation of study findings. The research team is committed to evaluating the possibility of sharing data in a manner that protects participant confidentiality and contributes to scientific knowledge.
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2025, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ningbo Medical Center Lihuili Hospital